GRAIL Inc.
- GRAL
- NASDAQ
- Medical - Diagnostics & Research
- Multi-Cancer Early Detection Testing
- Liquid Biopsy Diagnostics
- Cancer Screening (Galleri)
$122.42
Today +3.91%Quote Oct 19, 2026, 08:00 PM UTC
+53.12%over the last month
Max drawdown −23.5%From 1-month high −20.5%3 months +77.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About GRAIL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Employees
910
Founded
2015
Market value
$5.47B
Quote Oct 19
Floor
$108.52
11.4% below price
Resistance
$126.82
3.6% above price
Price vs analyst targets
8 analysts
Lowest target
$56.00Highest target
$175.00
$56.00Highest target
$175.00
- Price $122.42
- Average target $107.88
- Analysts' target range
Analysts' average target sits about 12% lower. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GRALPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free